Selectively targeting prostanoid E (EP) receptor-mediated cell signalling pathways: Implications for lung health and disease

Pulmonary Pharmacology and Therapeutics

Volumn 49, Issue , 2018, Pages 75-87

  Lebender, Leonard F ^a   Prünte, Laura ^a   Rumzhum, Nowshin N ^a   Ammit, Alaina J ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

1 ACETYL 2 (8 CHLORO 10,11 DIHYDRODIBENZ[B,F][1,4]OXAZEPINE 10 CARBONYL)HYDRAZINE; 11 DEOXY 16 PHENOXY 17,18,19,20 TETRANORPROSTAGLANDIN E1; 2 [4 (1 HYDROXYHEXYL)PHENYL] 5 OXOCYCLOPENTANEHEPTANOIC ACID; 3 [1 (2,4 DICHLOROBENZYL) 5 FLUORO 3 METHYL 1H INDOL 7 YL] N [(4,5 DICHLORO 2 THIENYL)SULFONYL]ACRYLAMIDE; 6 ISOPROPOXY 9 OXO 2 XANTHENECARBOXYLIC ACID; 6 [2 [5 CHLORO 2 (2,4 DIFLUOROBENZYLOXY)PHENYL] 1 CYCLOPENTENYL] 2 PYRIDINECARBOXYLIC ACID; 6 [3 (4 CHLORO 2 METHYLPHENYLSULFONYLAMINOMETHYL)BICYCLO[2.2.2]OCTAN 2 YL] 5 HEXENOIC ACID; BUTAPROST; CM 9; CP 544326; EVATANEPAG; GR 63799X; L 826266; MISOPROSTOL; ONO 8713; ONO AE 1 259; ONO AE 1 329; ONO AE 1 734; ONO AE 248; ONO AE 3 240; ONO DI 004; PF 04418948; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; PROSTAGLANDIN RECEPTOR STIMULATING AGENT; SC 51089; SULPROSTONE; TCS 2510; TEI 3356; TG 4 155; TG 6 10 1; TG 6 129; UNCLASSIFIED DRUG; UNINDEXED DRUG; ARACHIDONIC ACID;

ANGIOGENESIS; BRONCHODILATATION; COUGHING; DRUG BIOAVAILABILITY; HUMAN; KNOCKOUT MOUSE; LIGAND BINDING; LUNG BLOOD VESSEL; LUNG FUNCTION; MAST CELL DEGRANULATION; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; RESPIRATORY TRACT INFLAMMATION; REVIEW; SENESCENCE; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG DEVELOPMENT; DRUG EFFECT; LUNG; LUNG DISEASE; METABOLISM; MOUSE; PATHOPHYSIOLOGY; PROCEDURES;

ANIMALS; ARACHIDONIC ACID; DRUG DEVELOPMENT; HUMANS; LUNG; LUNG DISEASES; MICE; MICE, KNOCKOUT; RECEPTORS, PROSTAGLANDIN E; SIGNAL TRANSDUCTION;

EID: 85041680802     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2018.01.008     Document Type: Review

References (140)

1. Coleman, R.A., Smith, W.L., Narumiya, S., International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol. Rev. 46:2 (1994), 205–229.
2. Breyer, R.M., Bagdassarian, C.K., Myers, S.A., Breyer, M.D., Prostanoid receptors: subtypes and signaling. Annu. Rev. Pharmacol. Toxicol. 41 (2001), 661–690.
3. Rumzhum, N.N., Ammit, A.J., Cyclooxygenase 2: its regulation, role and impact in airway inflammation. Clin. Exp. Allergy 46:3 (March 2016), 397–410.
4. Regan, J.W., Bailey, T.J., Donello, J.E., Pierce, K.L., Pepperl, D.J., Zhang, D., Kedzie, K.M., Fairbairn, C.E., Bogardus, A.M., Woodward, D.F., et al. Molecular cloning and expression of human EP3 receptors: evidence of three variants with differing carboxyl termini. Br. J. Pharmacol. 112:2 (1994), 377–385.
5. Okuda-Ashitaka, E., Sakamoto, K., Ezashi, T., Miwa, K., Ito, S., Hayaishi, O., Suppression of prostaglandin E receptor signaling by the variant form of EP1 subtype. J. Biol. Chem. 271:49 (1996), 31255–31261.
6. Funk, C.D., Furci, L., FitzGerald, G.A., Grygorczyk, R., Rochette, C., Bayne, M.A., Abramovitz, M., Adam, M., Metters, K.M., Cloning and expression of a cDNA for the human prostaglandin E receptor EP1 subtype. J. Biol. Chem. 268:35 (1993), 26767–26772.
7. Ji, R., Chou, C.L., Xu, W., Chen, X.B., Woodward, D.F., Regan, J.W., EP1 prostanoid receptor coupling to G i/o up-regulates the expression of hypoxia-inducible factor-1 alpha through activation of a phosphoinositide-3 kinase signaling pathway. Mol. Pharmacol. 77:6 (2010), 1025–1036.
8. Watabe, A., Sugimoto, Y., Honda, A., Irie, A., Namba, T., Negishi, M., Ito, S., Narumiya, S., Ichikawa, A., Cloning and expression of cDNA for a mouse EP1 subtype of prostaglandin E receptor. J. Biol. Chem. 268:27 (1993), 20175–20178.
9. Katoh, H., Watabe, A., Sugimoto, Y., Ichikawa, A., Negishi, M., Characterization of the signal transduction of prostaglandin E receptor EP1 subtype in cDNA-transfected Chinese hamster ovary cells. Biochimica. et. biophysica acta 1244:1 (1995), 41–48.
10. Tabata, H., Tanaka, S., Sugimoto, Y., Kanki, H., Kaneko, S., Ichikawa, A., Possible coupling of prostaglandin E receptor EP(1) to TRP5 expressed in Xenopus laevis oocytes. Biochem. Biophys. Res. Commun. 298:3 (2002), 398–402.
11. Bastien, L., Sawyer, N., Grygorczyk, R., Metters, K.M., Adam, M., Cloning, functional expression, and characterization of the human prostaglandin E2 receptor EP2 subtype. J. Biol. Chem. 269:16 (1994), 11873–11877.
12. Regan, J.W., Bailey, T.J., Pepperl, D.J., Pierce, K.L., Bogardus, A.M., Donello, J.E., Fairbairn, C.E., Kedzie, K.M., Woodward, D.F., Gil, D.W., Cloning of a novel human prostaglandin receptor with characteristics of the pharmacologically defined EP2 subtype. Mol. Pharmacol. 46:2 (1994), 213–220.
13. Coleman, R.A., Grix, S.P., Head, S.A., Louttit, J.B., Mallett, A., Sheldrick, R.L., A novel inhibitory prostanoid receptor in piglet saphenous vein. Prostaglandins 47:2 (1994), 151–168.
14. Nishigaki, N., Negishi, M., Honda, A., Sugimoto, Y., Namba, T., Narumiya, S., Ichikawa, A., Identification of prostaglandin E receptor 'EP2' cloned from mastocytoma cells EP4 subtype. FEBS Lett. 364:3 (1995), 339–341.
15. Kiriyama, M., Ushikubi, F., Kobayashi, T., Hirata, M., Sugimoto, Y., Narumiya, S., Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br. J. Pharmacol. 122:2 (1997), 217–224.
16. Regan, J.W., EP2 and EP4 prostanoid receptor signaling. Life Sci. 74:2–3 (2003), 143–153.
17. Toh, H., Ichikawa, A., Narumiya, S., Molecular evolution of receptors for eicosanoids. FEBS Lett. 361:1 (1995), 17–21.
18. Billington, C.K., Hall, I.P., Novel cAMP signalling paradigms: therapeutic implications for airway disease. Br. J. Pharmacol. 166:2 (2012), 401–410.
19. Narumiya, S., Sugimoto, Y., Ushikubi, F., Prostanoid receptors: structures, properties, and functions. Physiol. Rev. 79:4 (1999), 1193–1226.
20. Desai, S., April, H., Nwaneshiudu, C., Ashby, B., Comparison of agonist-induced internalization of the human EP2 and EP4 prostaglandin receptors: role of the carboxyl terminus in EP4 receptor sequestration. Mol. Pharmacol. 58:6 (2000), 1279–1286.
21. Nishigaki, N., Negishi, M., Ichikawa, A., Two Gs-coupled prostaglandin E receptor subtypes, EP2 and EP4, differ in desensitization and sensitivity to the metabolic inactivation of the agonist. Mol. Pharmacol. 50:4 (1996), 1031–1037.
22. Fujino, H., West, K.A., Regan, J.W., Phosphorylation of glycogen synthase kinase-3 and stimulation of T-cell factor signaling following activation of EP2 and EP4 prostanoid receptors by prostaglandin E2. J. Biol. Chem. 277:4 (2002), 2614–2619.
23. Fujino, H., Regan, J.W., EP(4) prostanoid receptor coupling to a pertussis toxin-sensitive inhibitory G protein. Mol. Pharmacol. 69:1 (2006), 5–10.
24. Dale, T.C., Signal transduction by the Wnt family of ligands. Biochem. J. 329:Pt 2 (1998), 209–223.
25. Peifer, M., Polakis, P., Wnt signaling in oncogenesis and embryogenesis–a look outside the nucleus. Science 287:5458 (2000), 1606–1609.
26. Fujino, H., Regan, J.W., Prostanoid receptors and phosphatidylinositol 3-kinase: a pathway to cancer?. Trends Pharmacol. Sci. 24:7 (2003), 335–340.
27. Rodriguez-Viciana, P., Warne, P.H., Khwaja, A., Marte, B.M., Pappin, D., Das, P., Waterfield, M.D., Ridley, A., Downward, J., Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras. Cell 89:3 (1997), 457–467.
28. Naga Prasad, S.V., Barak, L.S., Rapacciuolo, A., Caron, M.G., Rockman, H.A., Agonist-dependent recruitment of phosphoinositide 3-kinase to the membrane by beta-adrenergic receptor kinase 1. A role in receptor sequestration. J. Biol. Chem. 276:22 (2001), 18953–18959.
29. Johannessen, M., Delghandi, M.P., Moens, U., What turns CREB on?. Cell Signal 16:11 (2004), 1211–1227.
30. Mayr, B., Montminy, M., Transcriptional regulation by the phosphorylation-dependent factor CREB. Nat. Rev. Mol. Cell Biol. 2:8 (2001), 599–609.
31. Fujino, H., Salvi, S., Regan, J.W., Differential regulation of phosphorylation of the cAMP response element-binding protein after activation of EP2 and EP4 prostanoid receptors by prostaglandin E2. Mol. Pharmacol. 68:1 (2005), 251–259.
32. Clarke, D.L., Belvisi, M.G., Hardaker, E., Newton, R., Giembycz, M.A., E-ring 8-isoprostanes are agonists at EP2- and EP4-prostanoid receptors on human airway smooth muscle cells and regulate the release of colony-stimulating factors by activating cAMP-dependent protein kinase. Mol. Pharmaco. 67:2 (2005), 383–393.
33. Hatae, N., Sugimoto, Y., Ichikawa, A., Prostaglandin receptors: advances in the study of EP3 receptor signaling. J. Biochem. 131:6 (2002), 781–784.
34. Audoly, L.P., Ma, L., Feoktistov, I., de Foe, S.K., Breyer, M.D., Breyer, R.M., Prostaglandin E-prostanoid-3 receptor activation of cyclic AMP response element-mediated gene transcription. J. Pharmacol. Exp. Ther. 289:1 (1999), 140–148.
35. Israel, D.D., Regan, J.W., EP(3) prostanoid receptor isoforms utilize distinct mechanisms to regulate ERK 1/2 activation. Biochimica et biophysica acta 1791:4 (2009), 238–245.
36. Kotani, M., Tanaka, I., Ogawa, Y., Suganami, T., Matsumoto, T., Muro, S., Yamamoto, Y., Sugawara, A., Yoshimasa, Y., Sagawa, N., Narumiya, S., Nakao, K., Multiple signal transduction pathways through two prostaglandin E receptor EP3 subtype isoforms expressed in human uterus. J. Clin. Endocrinol. Metab. 85:11 (2000), 4315–4322.
37. Bilson, H.A., Mitchell, D.L., Ashby, B., Human prostaglandin EP3 receptor isoforms show different agonist-induced internalization patterns. FEBS Lett. 572:1–3 (2004), 271–275.
38. Kotani, M., Tanaka, I., Ogawa, Y., Usui, T., Tamura, N., Mori, K., Narumiya, S., Yoshimi, T., Nakao, K., Structural organization of the human prostaglandin EP3 receptor subtype gene (PTGER3). Genomics 40:3 (1997), 425–434.
39. Schmid, A., Thierauch, K.H., Schleuning, W.D., Dinter, H., Splice variants of the human EP3 receptor for prostaglandin E2. Eur. J. Biochem. 228:1 (1995), 23–30.
40. Jin, J., Mao, G.F., Ashby, B., Constitutive activity of human prostaglandin E receptor EP3 isoforms. Br. J. Pharmacol. 121:2 (1997), 317–323.
41. Chung, K.F., Evaluation of selective prostaglandin E2 (PGE2) receptor agonists as therapeutic agents for the treatment of asthma. Sci. STKE 2005, 303, 2005 pe47.
42. Burkey, T.H., Regan, J.W., Activation of mitogen-activated protein kinase by the human prostaglandin EP3A receptor. Biochem. Biophys. Res. Commun. 211:1 (1995), 152–158.
43. Konger, R.L., Brouxhon, S., Partillo, S., VanBuskirk, J., Pentland, A.P., The EP3 receptor stimulates ceramide and diacylglycerol release and inhibits growth of primary keratinocytes. Exp. Dermatol. 14:12 (2005), 914–922.
44. Norel, X., de Montpreville, V., Brink, C., Vasoconstriction induced by activation of EP1 and EP3 receptors in human lung: effects of ONO-AE-248, ONO-DI-004, ONO-8711 or ONO-8713. Prostaglandins Other Lipid Mediat. 74:1–4 (2004), 101–112.
45. Suzawa, T., Miyaura, C., Inada, M., Maruyama, T., Sugimoto, Y., Ushikubi, F., Ichikawa, A., Narumiya, S., Suda, T., The role of prostaglandin E receptor subtypes (EP1, EP2, EP3, and EP4) in bone resorption: an analysis using specific agonists for the respective EPs. Endocrinology 141:4 (2000), 1554–1559.
46. Watanabe, K., Kawamori, T., Nakatsugi, S., Ohta, T., Ohuchida, S., Yamamoto, H., Maruyama, T., Kondo, K., Ushikubi, F., Narumiya, S., Sugimura, T., Wakabayashi, K., Role of the prostaglandin E receptor subtype EP1 in colon carcinogenesis. Cancer Res. 59:20 (1999), 5093–5096.
47. Watanabe, K., Kawamori, T., Nakatsugi, S., Ohta, T., Ohuchida, S., Yamamoto, H., Maruyama, T., Kondo, K., Narumiya, S., Sugimura, T., Wakabayashi, K., Inhibitory effect of a prostaglandin E receptor subtype EP(1) selective antagonist, ONO-8713, on development of azoxymethane-induced aberrant crypt foci in mice. Cancer Lett. 156:1 (2000), 57–61.
48. Giblin, G.M., Bit, R.A., Brown, S.H., Chaignot, H.M., Chowdhury, A., Chessell, I.P., Clayton, N.M., Coleman, T., Hall, A., Hammond, B., Hurst, D.N., Michel, A.D., Naylor, A., Novelli, R., Scoccitti, T., Spalding, D., Tang, S.P., Wilson, A.W., Wilson, R., The discovery of 6-[2-(5-chloro-2-{[(2,4-difluorophenyl)methyl]oxy}phenyl)-1-cyclopenten-1-yl]-2-p yridinecarboxylic acid, GW848687X, a potent and selective prostaglandin EP1 receptor antagonist for the treatment of inflammatory pain. Bioorg. Med. Chem. Lett. 17:2 (2007), 385–389.
49. Hallinan, E.A., Hagen, T.J., Husa, R.K., Tsymbalov, S., Rao, S.N., vanHoeck, J.P., Rafferty, M.F., Stapelfeld, A., Savage, M.A., Reichman, M., N-substituted dibenzoxazepines as analgesic PGE2 antagonists. J. Med. Chem. 36:22 (1993), 3293–3299.
50. Durocher, Y., Perret, S., Thibaudeau, E., Gaumond, M.H., Kamen, A., Stocco, R., Abramovitz, M., A reporter gene assay for high-throughput screening of G-protein-coupled receptors stably or transiently expressed in HEK293 EBNA cells grown in suspension culture. Anal Biochem. 284:2 (2000), 316–326.
51. Abramovitz, M., Adam, M., Boie, Y., Carriere, M., Denis, D., Godbout, C., Lamontagne, S., Rochette, C., Sawyer, N., Tremblay, N.M., Belley, M., Gallant, M., Dufresne, C., Gareau, Y., Ruel, R., Juteau, H., Labelle, M., Ouimet, N., Metters, K.M., The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochimica et biophysica acta 1483:2 (2000), 285–293.
52. Hung, G.H., Jones, R.L., Lam, F.F., Chan, K.M., Hidaka, H., Suzuki, M., Sasaki, Y., Investigation of the pronounced synergism between prostaglandin E2 and other constrictor agents on rat femoral artery. Prostaglandins Leukot Essent Fatty Acids 74:6 (2006), 401–415.
53. Sanner, J., Prostaglandin inhibition with a dibenzoxazepine hydrazide derivative and morphine. Ann. N. Y. Acad. Sci. 180 (1971), 396–409.
54. Rakovska, A., Milenov, K., Antagonistic effect of SC-19220 on the responses of Guinea-pig gastric muscles to prostaglandins E1, E2 and F2 alpha. Arch. Int. Pharmacodyn. Ther. 268:1 (1984), 59–69.
55. Coleman, R.A., Kennedy, I., Characterisation of the prostanoid receptors mediating contraction of Guinea-pig isolated trachea. Prostaglandins 29:3 (1985), 363–375.
56. Wilson, R.J., Rhodes, S.A., Wood, R.L., Shield, V.J., Noel, L.S., Gray, D.W., Giles, H., Functional pharmacology of human prostanoid EP2 and EP4 receptors. Euro. J. Pharmacol. 501:1–3 (2004), 49–58.
57. Tani, K., Naganawa, A., Ishida, A., Egashira, H., Sagawa, K., Harada, H., Ogawa, M., Maruyama, T., Ohuchida, S., Nakai, H., Kondo, K., Toda, M., Design and synthesis of a highly selective EP2-receptor agonist. Bioorg. Med. Chem. Lett. 11:15 (2001), 2025–2028.
58. Tani, K., Naganawa, A., Ishida, A., Sagawa, K., Harada, H., Ogawa, M., Maruyama, T., Ohuchida, S., Nakai, H., Kondo, K., Toda, M., Development of a highly selective EP2-receptor agonist. Part 1: identification of 16-hydroxy-17,17-trimethylene PGE2 derivatives. Bioorg. Med. Chem. 10:4 (2002), 1093–1106.
59. Ganesh, T., Prostanoid receptor EP2 as a therapeutic target. J. Med. Chem. 57:11 (2014), 4454–4465.
60. Aso, H., Ito, S., Mori, A., Suganuma, N., Morioka, M., Takahara, N., Kondo, M., Hasegawa, Y., Differential regulation of airway smooth muscle cell migration by E-prostanoid receptor subtypes. Am. J. Resp. Cell Mol. Biol. 48:3 (2013), 322–329.
61. Nials, A.T., Vardey, C.J., Denyer, L.H., Thomas, M., Sparrow, S.J., Shepherd, G.D., Coleman, R.A., AH13205, a selective prostanoid EP2-receptor agonist. Cardiovas. Drug Rev. 11:2 (1993), 165–179.
62. Prasanna, G., Carreiro, S., Anderson, S., Gukasyan, H., Sartnurak, S., Younis, H., Gale, D., Xiang, C., Wells, P., Dinh, D., Almaden, C., Fortner, J., Toris, C., Niesman, M., Lafontaine, J., Krauss, A., Effect of PF-04217329 a prodrug of a selective prostaglandin EP(2) agonist on intraocular pressure in preclinical models of glaucoma. Exp. Eye Res. 93:3 (2011), 256–264.
63. Woodward, D.F., Pepperl, D.J., Burkey, T.H., Regan, J.W., 6-Isopropoxy-9-oxoxanthene-2-carboxylic acid (AH 6809), a human EP2 receptor antagonist. Biochem. Pharmacol. 50:10 (1995), 1731–1733.
64. af Forselles, K.J., Root, J., Clarke, T., Davey, D., Aughton, K., Dack, K., Pullen, N., In vitro and in vivo characterization of PF-04418948, a novel, potent and selective prostaglandin EP(2) receptor antagonist. Br. J. Pharmacol. 164:7 (2011), 1847–1856.
65. Birrell, M.A., Nials, A.T., At last, a truly selective EP(2) receptor antagonist. Br. J. Pharmacol. 164:7 (2011), 1845–1846.
66. Birrell, M.A., Maher, S.A., Buckley, J., Dale, N., Bonvini, S., Raemdonck, K., Pullen, N., Giembycz, M.A., Belvisi, M.G., Selectivity profiling of the novel EP2 receptor antagonist, PF-04418948, in functional bioassay systems: atypical affinity at the Guinea pig EP2 receptor. Br. J. Pharmacol. 168:1 (2013), 129–138.
67. Jiang, J., Ganesh, T., Du, Y., Quan, Y., Serrano, G., Qui, M., Speigel, I., Rojas, A., Lelutiu, N., Dingledine, R., Small molecule antagonist reveals seizure-induced mediation of neuronal injury by prostaglandin E2 receptor subtype EP2. Proc. Natl. Acad. Sci. U. S. A. 109:8 (2012), 3149–3154.
68. Ganesh, T., Jiang, J., Shashidharamurthy, R., Dingledine, R., Discovery and characterization of carbamothioylacrylamides as EP selective antagonists. ACS Med. Chem. Lett. 4:7 (2013), 616–621.
69. Zacharowski, K., Olbrich, A., Thiemermann, C., Reduction of myocardial injury by the EP3 receptor agonist TEI-3356. Role of protein kinase C and of K(ATP)-channels. Euro. J. Pharmacol. 367:1 (1999), 33–39.
70. Okada, Y., Hara, A., Ma, H., Xiao, C.Y., Takahata, O., Kohgo, Y., Narumiya, S., Ushikubi, F., Characterization of prostanoid receptors mediating contraction of the gastric fundus and ileum: studies using mice deficient in prostanoid receptors. Br. J. Pharmacol. 131:4 (2000), 745–755.
71. Boie, Y., Stocco, R., Sawyer, N., Slipetz, D.M., Ungrin, M.D., Neuschafer-Rube, F., Puschel, G.P., Metters, K.M., Abramovitz, M., Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes. Euro. J. Pharmacol. 340:2–3 (1997), 227–241.
72. Nakagawa, T., Minami, M., Katsumata, S., Ienaga, Y., Satoh, M., Suppression of naloxone-precipitated withdrawal jumps in morphine-dependent mice by stimulation of prostaglandin EP3 receptor. Br. J. Pharmacol. 116:6 (1995), 2661–2666.
73. Irie, A., Sugimoto, Y., Namba, T., Harazono, A., Honda, A., Watabe, A., Negishi, M., Narumiya, S., Ichikawa, A., Third isoform of the prostaglandin-E-receptor EP3 subtype with different C-terminal tail coupling to both stimulation and inhibition of adenylate cyclase. Eur. J. Biochem. 217:1 (1993), 313–318.
74. Negishi, M., Harazono, A., Sugimoto, Y., Hazato, A., Kurozumi, S., Ichikawa, A., TEI-3356, a highly selective agonist for the prostaglandin EP3 receptor. Prostaglandins 48:5 (1994), 275–283.
75. Amano, H., Hayashi, I., Endo, H., Kitasato, H., Yamashina, S., Maruyama, T., Kobayashi, M., Satoh, K., Narita, M., Sugimoto, Y., Murata, T., Yoshimura, H., Narumiya, S., Majima, M., Host prostaglandin E(2)-EP3 signaling regulates tumor-associated angiogenesis and tumor growth. J. Exp. Med. 197:2 (2003), 221–232.
76. Maher, S.A., Birrell, M.A., Belvisi, M.G., Prostaglandin E2 mediates cough via the EP3 receptor: implications for future disease therapy. Am. J. Res. Critical Care Med. 180:10 (2009), 923–928.
77. Oliva, P., Berrino, L., de Novellis, V., Palazzo, E., Marabese, I., Siniscalco, D., Scafuro, M., Mariani, L., Rossi, F., Maione, S., Role of periaqueductal grey prostaglandin receptors in formalin-induced hyperalgesia. Euro. J. Pharmaco. 530:1–2 (2006), 40–47.
78. Su, X., Leon, L.A., Wu, C.W., Morrow, D.M., Jaworski, J.P., Hieble, J.P., Lashinger, E.S., Jin, J., Edwards, R.M., Laping, N.J., Modulation of bladder function by prostaglandin EP3 receptors in the central nervous system. Am. J. Physiol. Renal. Physiol. 295:4 (2008), F984–F994.
79. Singh, J., Zeller, W., Zhou, N., Hategen, G., Mishra, R., Polozov, A., Yu, P., Onua, E., Zhang, J., Zembower, D., Kiselyov, A., Ramirez, J.L., Sigthorsson, G., Bjornsson, J.M., Thorsteinsdottir, M., Andresson, T., Bjarnadottir, M., Magnusson, O., Fabre, J.E., Stefansson, K., Gurney, M.E., Antagonists of the EP3 receptor for prostaglandin E2 are novel antiplatelet agents that do not prolong bleeding. ACS Chem. Biol. 4:2 (2009), 115–126.
80. Billot, X., Chateauneuf, A., Chauret, N., Denis, D., Greig, G., Mathieu, M.C., Metters, K.M., Slipetz, D.M., Young, R.N., Discovery of a potent and selective agonist of the prostaglandin EP4 receptor. Bioorg. Med. Chem. Lett. 13:6 (2003), 1129–1132.
81. Xiao, Y., Araldi, G.L., Zhao, Z., Brugger, N., Karra, S., Fischer, D., Palmer, E., Discovery of novel prostaglandin analogs of PGE2 as potent and selective EP2 and EP4 receptor agonists. Bioorg. Med. Chem. Lett. 17:15 (2007), 4323–4327.
82. Kabashima, K., Saji, T., Murata, T., Nagamachi, M., Matsuoka, T., Segi, E., Tsuboi, K., Sugimoto, Y., Kobayashi, T., Miyachi, Y., Ichikawa, A., Narumiya, S., The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut. J. Clin. Invest. 109:7 (2002), 883–893.
83. Buckley, J., Birrell, M.A., Maher, S.A., Nials, A.T., Clarke, D.L., Belvisi, M.G., EP4 receptor as a new target for bronchodilator therapy. Thorax 66:12 (2011), 1029–1035.
84. Benyahia, C., Gomez, I., Kanyinda, L., Boukais, K., Danel, C., Leseche, G., Longrois, D., Norel, X., PGE(2) receptor (EP(4)) agonists: potent dilators of human bronchi and future asthma therapy?. Pulm. Pharmacol. Ther. 25:1 (2012), 115–118.
85. Luschnig-Schratl, P., Sturm, E.M., Konya, V., Philipose, S., Marsche, G., Frohlich, E., Samberger, C., Lang-Loidolt, D., Gattenlohner, S., Lippe, I.T., Peskar, B.A., Schuligoi, R., Heinemann, A., EP4 receptor stimulation down-regulates human eosinophil function. Cell Mol. Life Sci. 68:21 (2011), 3573–3587.
86. Aso, H., Ito, S., Mori, A., Morioka, M., Suganuma, N., Kondo, M., Imaizumi, K., Hasegawa, Y., Prostaglandin E2 enhances interleukin-8 production via EP4 receptor in human pulmonary microvascular endothelial cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 302:2 (2012), L266–L273.
87. Foudi, N., Kotelevets, L., Louedec, L., Leseche, G., Henin, D., Chastre, E., Norel, X., Vasorelaxation induced by prostaglandin E2 in human pulmonary vein: role of the EP4 receptor subtype. Br. J. Pharmacol. 154:8 (2008), 1631–1639.
88. Woodward, D.F., Jones, R.L., Narumiya, S., International Union of Basic and Clinical Pharmacology. LXXXIII: classification of prostanoid receptors, updating 15 years of progress. Pharmacol. Rev. 63:3 (2011), 471–538.
89. Wilson, R.J., Giblin, G.M., Roomans, S., Rhodes, S.A., Cartwright, K.A., Shield, V.J., Brown, J., Wise, A., Chowdhury, J., Pritchard, S., Coote, J., Noel, L.S., Kenakin, T., Burns-Kurtis, C.L., Morrison, V., Gray, D.W., Giles, H., GW627368X ((N-{2-[4-(4,9-diethoxy-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl)phenyl]acetyl} benzene sulphonamide): a novel, potent and selective prostanoid EP4 receptor antagonist. Br. J. Pharmacol. 148:3 (2006), 326–339.
90. Davis, T.L., Sharif, N.A., Pharmacological characterization of [(3)H]-prostaglandin E(2) binding to the cloned human EP(4) prostanoid receptor. Br. J. Pharmacol. 130:8 (2000), 1919–1926.
91. Nakao, K., Murase, A., Ohshiro, H., Okumura, T., Taniguchi, K., Murata, Y., Masuda, M., Kato, T., Okumura, Y., Takada, J., CJ-023,423, a novel, potent and selective prostaglandin EP4 receptor antagonist with antihyperalgesic properties. J. Pharmacol. Exp. Ther. 322:2 (2007), 686–694.
92. Murase, A., Taniguchi, Y., Tonai-Kachi, H., Nakao, K., Takada, J., In vitro pharmacological characterization of CJ-042794, a novel, potent, and selective prostaglandin EP(4) receptor antagonist. Life Sci. 82:3–4 (2008), 226–232.
93. Colucci, J., Boyd, M., Berthelette, C., Chiasson, J.F., Wang, Z., Ducharme, Y., Friesen, R., Wrona, M., Levesque, J.F., Denis, D., Mathieu, M.C., Stocco, R., Therien, A.G., Clarke, P., Rowland, S., Xu, D., Han, Y., Discovery of 4-[1-[([1-[4-(trifluoromethyl)benzyl]-1H-indol-7-yl]carbonyl)amino]cyclopropyl]be nzoic acid (MF-766), a highly potent and selective EP4 antagonist for treating inflammatory pain. Bioorg. Med. Chem. Lett. 20:12 (2010), 3760–3763.
94. Takayama, K., Garcia-Cardena, G., Sukhova, G.K., Comander, J., Gimbrone, M.A. Jr., Libby, P., Prostaglandin E2 suppresses chemokine production in human macrophages through the EP4 receptor. J. Biol. Chem. 277:46 (2002), 44147–44154.
95. Machwate, M., Harada, S., Leu, C.T., Seedor, G., Labelle, M., Gallant, M., Hutchins, S., Lachance, N., Sawyer, N., Slipetz, D., Metters, K.M., Rodan, S.B., Young, R., Rodan, G.A., Prostaglandin receptor EP(4) mediates the bone anabolic effects of PGE(2). Mol. Pharmacol. 60:1 (2001), 36–41.
96. Maubach, K.A., Davis, R.J., Clark, D.E., Fenton, G., Lockey, P.M., Clark, K.L., Oxford, A.W., Hagan, R.M., Routledge, C., Coleman, R.A., BGC20-1531, a novel, potent and selective prostanoid EP receptor antagonist: a putative new treatment for migraine headache. Br. J. Pharmacol. 156:2 (2009), 316–327.
97. Ushikubi, F., Segi, E., Sugimoto, Y., Murata, T., Matsuoka, T., Kobayashi, T., Hizaki, H., Tuboi, K., Katsuyama, M., Ichikawa, A., Tanaka, T., Yoshida, N., Narumiya, S., Impaired febrile response in mice lacking the prostaglandin E receptor subtype EP3. Nature 395:6699 (1998), 281–284.
98. Birrell, M.A., Maher, S.A., Dekkak, B., Jones, V., Wong, S., Brook, P., Belvisi, M.G., Anti-inflammatory effects of PGE2 in the lung: role of the EP4 receptor subtype. Thorax 70:8 (2015), 740–747.
99. Jones, V.C., Birrell, M.A., Maher, S.A., Griffiths, M., Grace, M., O'Donnell, V.B., Clark, S.R., Belvisi, M.G., Role of EP2 and EP4 receptors in airway microvascular leak induced by prostaglandin E2. Brit. J. Pharmacol. 173:6 (2016), 992–1004.
100. Xia, Y.C., Redhu, N.S., Moir, L.M., Koziol-White, C., Ammit, A.J., Al-Alwan, L., Camoretti-Mercado, B., Clifford, R.L., Pro-inflammatory and immunomodulatory functions of airway smooth muscle: emerging concepts. Pulm. Pharmacol. Ther. 26:1 (2013), 64–74.
101. Clarke, D.L., Belvisi, M.G., Smith, S.J., Hardaker, E., Yacoub, M.H., Meja, K.K., Newton, R., Slater, D.M., Giembycz, M.A., Prostanoid receptor expression by human airway smooth muscle cells and regulation of the secretion of granulocyte colony-stimulating factor. Am. J. Physiol. Lung Cell. Mol. Physiol. 288:2 (2005), L238–L250.
102. Bradbury, D., Clarke, D., Seedhouse, C., Corbett, L., Stocks, J., Knox, A., Vascular endothelial growth factor induction by prostaglandin E2 in human airway smooth muscle cells is mediated by E prostanoid EP2/EP4 receptors and SP-1 transcription factor binding sites. J. Biol. Chem. 280:34 (2005), 29993–30000.
103. Mori, A., Ito, S., Morioka, M., Aso, H., Kondo, M., Sokabe, M., Hasegawa, Y., Effects of specific prostanoid EP receptor agonists on cell proliferation and intracellular Ca(2+) concentrations in human airway smooth muscle cells. Euro. J. Pharmaco. 659:1 (2011), 72–78.
104. Khor, Y.H., Teoh, A.K., Lam, S.M., Mo, D.C., Weston, S., Reid, D.W., Walters, E.H., Increased vascular permeability precedes cellular inflammation as asthma control deteriorates. Clin. Exp. Allergy 39:11 (2009), 1659–1667.
105. Bessa, V., Loukides, S., Hillas, G., Delimpoura, V., Simoes, D., Kontogianni, K., Papiris, S., Kostikas, K., Alchanatis, M., Bakakos, P., Levels of angiopoietins 1 and 2 in induced sputum supernatant in patients with COPD. Cytokine 58:3 (2012), 455–460.
106. Walch, L., de Montpreville, V., Brink, C., Norel, X., Prostanoid EP(1)- and TP-receptors involved in the contraction of human pulmonary veins. Br. J. Pharmacol. 134:8 (2001), 1671–1678.
107. Ammit, A.J., Bekir, S.S., Johnson, P.R., Hughes, J.M., Armour, C.L., Black, J.L., Mast cell numbers are increased in the smooth muscle of human sensitized isolated bronchi. Am. J. Res. Crit. Care Med. 155:3 (1997), 1123–1129.
108. Page, S., Ammit, A.J., Black, J.L., Armour, C.L., Human mast cell and airway smooth muscle cell interactions: implications for asthma. Am. J. Physiol. Lung Cellular Mol. Physiol. 281:6 (2001), L1313–L1323.
109. Brightling, C.E., Ammit, A.J., Kaur, D., Black, J.L., Wardlaw, A.J., Hughes, J.M., Bradding, P., The CXCL10/CXCR3 axis mediates human lung mast cell migration to asthmatic airway smooth muscle. Am. J. Res. Crit. Care Med. 171:10 (2005), 1103–1108.
110. Drury, D.E., Chong, L.K., Ghahramani, P., Peachell, P.T., Influence of receptor reserve on beta-adrenoceptor-mediated responses in human lung mast cells. Br. J. Pharmacol. 124:4 (1998), 711–718.
111. Kay, L.J., Yeo, W.W., Peachell, P.T., Prostaglandin E2 activates EP2 receptors to inhibit human lung mast cell degranulation. Br. J. Pharmacol. 147:7 (2006), 707–713.
112. Kay, L.J., Gilbert, M., Pullen, N., Skerratt, S., Farrington, J., Seward, E.P., Peachell, P.T., Characterization of the EP receptor subtype that mediates the inhibitory effects of prostaglandin E2 on IgE-dependent secretion from human lung mast cells. Clin. Exp. Allergy 43:7 (2013), 741–751.
113. Safholm, J., Manson, M.L., Bood, J., Delin, I., Orre, A.C., Bergman, P., Al-Ameri, M., Dahlen, S.E., Adner, M., Prostaglandin E2 inhibits mast cell-dependent bronchoconstriction in human small airways through the E prostanoid subtype 2 receptor. J. Allergy Clin. Immunol. 136:5 (2015), 1232–1239 e1.
114. Kippelen, P., Anderson, S.D., Pathogenesis of exercise-induced bronchoconstriction. Immunol. Allergy Clin. N. Am. 33:3 (2013), 299–312 (vii).
115. Torres-Atencio, I., Ainsua-Enrich, E., de Mora, F., Picado, C., Martin, M., Prostaglandin E2 prevents hyperosmolar-induced human mast cell activation through prostanoid receptors EP2 and EP4. PLoS One, 9(10), 2014, e110870.
116. Pavord, I.D., Tattersfield, A.E., Bronchoprotective role for endogenous prostaglandin E2. Lancet 345:8947 (1995), 436–438.
117. Norel, X., Walch, L., Labat, C., Gascard, J.P., Dulmet, E., Brink, C., Prostanoid receptors involved in the relaxation of human bronchial preparations. Br. J. Pharmacol. 126:4 (1999), 867–872.
118. Costello, J.F., Dunlop, L.S., Gardiner, P.J., Characteristics of prostaglandin induced cough in man. Br. J. Clin. Pharmacol. 20:4 (1985), 355–359.
119. Maher, S.A., Belvisi, M.G., Prostanoids and the cough reflex. Lung 188:Suppl 1 (2010), S9–S12.
120. Grace, M., Birrell, M.A., Dubuis, E., Maher, S.A., Belvisi, M.G., Transient receptor potential channels mediate the tussive response to prostaglandin E2 and bradykinin. Thorax 67:10 (2012), 891–900.
121. Bonvini, S.J., Belvisi, M.G., Cough and airway disease: the role of ion channels. Pulm. Pharmacol. Ther. 47 (2017 Dec), 21–28, 10.1016/j.pupt.2017.06.009 Epub 2017 Jun 29.
122. Huang, S.K., White, E.S., Wettlaufer, S.H., Grifka, H., Hogaboam, C.M., Thannickal, V.J., Horowitz, J.C., Peters-Golden, M., Prostaglandin E(2) induces fibroblast apoptosis by modulating multiple survival pathways. FASEB J 23:12 (2009), 4317–4326.
123. Ikari, J., Michalski, J.M., Iwasawa, S., Gunji, Y., Nogel, S., Park, J.H., Nelson, A.J., Farid, M., Wang, X., Schulte, N., Basma, H., Toews, M.L., Feghali-Bostwick, C., Tenor, H., Liu, X., Rennard, S.I., Phosphodiesterase-4 inhibition augments human lung fibroblast vascular endothelial growth factor production induced by prostaglandin E2. Am. J. Resp. Cell Mol. Biol. 49:4 (2013), 571–581.
124. Barnes, P.J., Senescence in COPD and its comorbidities. Ann. Rev. Physiol. 79 (2017), 517–539.
125. Dagouassat, M., Gagliolo, J.M., Chrusciel, S., Bourin, M.C., Duprez, C., Caramelle, P., Boyer, L., Hue, S., Stern, J.B., Validire, P., Longrois, D., Norel, X., Dubois-Rande, J.L., Le Gouvello, S., Adnot, S., Boczkowski, J., The cyclooxygenase-2-prostaglandin E2 pathway maintains senescence of chronic obstructive pulmonary disease fibroblasts. Am. J. Resp. Crit. Care Med. 187:7 (2013), 703–714.
126. Knox, A.J., Prostanoids as anti-inflammatory therapy: separating the good from the bad. Thorax 70:8 (2015), 711–712.
127. Ammit, A.J., Hoffman, R.K., Amrani, Y., Lazaar, A.L., Hay, D.W., Torphy, T.J., Penn, R.B., Panettieri, R.A. Jr., Tumor necrosis factor-alpha-induced secretion of RANTES and interleukin-6 from human airway smooth-muscle cells. Modulation by cyclic adenosine monophosphate. Am. J. Resp. Cell and Mol. Biol. 23:6 (2000), 794–802.
128. Lazzeri, N., Belvisi, M.G., Patel, H.J., Yacoub, M.H., Chung, K.F., Mitchell, J.A., Effects of prostaglandin E2 and cAMP elevating drugs on GM-CSF release by cultured human airway smooth muscle cells. Relevance to asthma therapy. Am. J. Resp. Cell and Mol. Biol. 24:1 (2001), 44–48.
129. Clarke, D.L., Belvisi, M.G., Catley, M.C., Yacoub, M.H., Newton, R., Giembycz, M.A., Identification in human airways smooth muscle cells of the prostanoid receptor and signalling pathway through which PGE2 inhibits the release of GM-CSF. Br. J. Pharmacol. 141:7 (2004), 1141–1150.
130. Kaur, M., Chivers, J.E., Giembycz, M.A., Newton, R., Long-acting beta2-adrenoceptor agonists synergistically enhance glucocorticoid-dependent transcription in human airway epithelial and smooth muscle cells. Mol. Pharmacol. 73:1 (2008), 203–214.
131. Billington, C.K., Ojo, O.O., Penn, R.B., Ito, S., cAMP regulation of airway smooth muscle function. Pulm. Pharmacol. Ther. 26:1 (2013), 112–120.
132. Ammit, A.J., Lazaar, A.L., Irani, C., O'Neill, G.M., Gordon, N.D., Amrani, Y., Penn, R.B., Panettieri, R.A. Jr., Tumor necrosis factor-alpha-induced secretion of RANTES and interleukin-6 from human airway smooth muscle cells: modulation by glucocorticoids and beta-agonists. Am. J. Resp. Cell and Mol. Biol. 26:4 (2002), 465–474.
133. Manetsch, M., Rahman, M.M., Patel, B.S., Ramsay, E.E., Rumzhum, N.N., Alkhouri, H., Ge, Q., Ammit, A.J., Long-acting beta2-agonists increase fluticasone propionate-induced mitogen-activated protein kinase phosphatase 1 (MKP-1) in airway smooth muscle cells. PLoS One, 8(3), 2013, e59635.
134. Che, W., Manetsch, M., Quante, T., Rahman, M.M., Patel, B.S., Ge, Q., Ammit, A.J., Sphingosine 1-phosphate induces MKP-1 expression via p38 MAPK- and CREB-mediated pathways in airway smooth muscle cells. Biochimica et biophysica acta 1823:10 (2012), 1658–1665.
135. Manetsch, M., Ramsay, E.E., King, E.M., Seidel, P., Che, W., Ge, Q., Hibbs, D.E., Newton, R., Ammit, A.J., Corticosteroids and beta(2)-agonists upregulate mitogen-activated protein kinase phosphatase 1: in vitro mechanisms. Br. J. Pharmacol. 166:7 (2012), 2049–2059.
136. Patel, B.S., Prabhala, P., Oliver, B.G., Ammit, A.J., Inhibitors of phosphodiesterase 4, but not phosphodiesterase 3, increase beta2-agonist-induced expression of antiinflammatory mitogen-activated protein kinase phosphatase 1 in airway smooth muscle cells. Am. J. Resp. Cell and Mol. Biol. 52:5 (2015), 634–640.
137. Patel, B.S., Rahman, M.M., Baehring, G., Xenaki, D., Tang, F.S., Oliver, B.G., Ammit, A.J., Roflumilast N-Oxide in combination with formoterol enhances the antiinflammatory effect of dexamethasone in airway smooth muscle cells. Am. J. Resp. Cell and Mol. Biol. 56:4 (2017), 532–538.
138. Rumzhum, N.N., Ammit, A.J., Prostaglandin E2 induces expression of MAPK phosphatase 1 (MKP-1) in airway smooth muscle cells. Euro. J. Pharmacol. 782 (2016), 1–5.
139. Gill, S.K., Yao, Y., Kay, L.J., Bewley, M.A., Marriott, H.M., Peachell, P.T., The anti-inflammatory effects of PGE2 on human lung macrophages are mediated by the EP4 receptor. Br. J. Pharmacol. 173:21 (2016), 3099–3109.
140. Konya, V., Maric, J., Jandl, K., Luschnig, P., Aringer, I., Lanz, I., Platzer, W., Theiler, A., Barnthaler, T., Frei, R., Marsche, G., Marsh, L.M., Olschewski, A., Lippe, I.T., Heinemann, A., Schuligoi, R., Activation of EP receptors prevents endotoxin-induced neutrophil infiltration into the airways and enhances microvascular barrier function. Br. J. Pharmacol. 172:18 (September 2015), 4454–4468.